Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Classification System Identifies Prostate Cancer Patients Who May Benefit from Combined Immune and Radiation Therapies

By LabMedica International staff writers
Posted on 22 Dec 2020
A novel classification system is expected to aid in the subtyping of aggressive prostate cancers in patients who may benefit from combined immune and radiation therapies.

Prostate cancer is graded from 1 to 5 based on how aggressive it is, with 5 being the most aggressive. More...
Patients with 4/5 grade cancers are at the highest risk of poor outcomes or death from the disease. However, currently there are no immunologic or genomic indicators for determination of the best course of treatment for this group of patients.

Investigators at the Moffitt Cancer Center & Research Institute (Tampa, FL, USA) employed two classifiers – the tumor immune content score (ICS) and the Decipher genomic classifier - to assess whether transcriptomic interactions between the two classifiers could identify the most lethal subsets of grade 4/5 prostate cancers. The ICS was derived from the mean expression of 264 immune cell-specific genes, while the Decipher score was based on 22 RNA biomarkers that predicted the probability that a cancer would spread.

For the current study, the investigators analyzed data from 8,071 prostate cancer patient samples of any disease grade (6,071 prostatectomy and 2,000 treatment naïve) in the Decipher Genomics Resource Information Database (GRID) registry. Each patient sample also received an ICS rating.

The samples were separated into four distinct immuno/genomic subsets based on the results: ICS high/Decipher high, ICS low/Decipher high, ICS high/Decipher low, and ICS low/Decipher low.

Results of the analyses revealed that approximately 25% of all grade 4/5 patient samples were in the ICS high/Decipher high subset. The ICS high/Decipher high subtype was associated with increased sensitivity to radiotherapy. Additionally, the ICS high/Decipher high subtype had a significantly higher risk of distant metastasis as compared with the ICS low/Decipher low subtype.

The creation of these novel immuno/genomic subtypes established a very strong synergistic interaction between ICS and Decipher in identifying grade 4/5 prostate cancer patients who are likely to experience the most lethal outcomes.

"Our results will aid in the subtyping of aggressive prostate cancer patients who may benefit from combined immune-radiotherapy modalities," said first author Dr. Kosj Yamoah, director of cancer disparities research at the Moffitt Cancer Center.

The study was published in the December 7, 2020, online edition of the journal European Urology.

Related Links:
Moffitt Cancer Center & Research Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Nucleic Acid Purification Instrument
QIAsymphony Connect
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.